Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies
Details : Under the collaboration, Phenomic and Astellas will explore the ability of antibodies, developed by Phenomic and directed at a novel target of the tumor stroma identified with Phenomic’s scTx platform, to enhance cell therapy approaches for the treatme...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $509.0 million
Deal Type : Collaboration
Details : The collaboration will leverage Phenomic’s expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer’s efforts to develop first-in-class medicines important i...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $9.0 million
November 29, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $509.0 million
Deal Type : Collaboration
Reset All
